Ivantis Inc. expanded its presence in the novel drugs and devices to lower intraocular pressure market with the launch of Hydrus microstent: a device used in minimally invasive glaucoma surgery

 

Increasing approval of drugs and devices associated with the treatment of glaucoma from regulatory bodies is projected to foster the growth of the novel drugs and devices to lower intraocular pressure market.  For instance, in May 2019, Ivantis Inc. received an approval from the U.S. Food and Drug Administration (FDA) for Hydrus microstent. It is a device used in minimally invasive glaucoma surgery. It is developed to lower eye pressure in patients with open-angle glaucoma.

North America is expected to lead the global novel drugs and devices to lower intraocular pressure market over the forecast period due to increasing FDA approval for drug launch. For instance, in September 2018, Sun Pharmaceuticals Industries Ltd. received approval from U.S. FDA for Xelpros (latanoprost ophthalmic emulsion) for the treatment of glaucoma. It reduces the elevated intraocular pressure in the eye and has been designed with the help of Swollen Micelle Microemulsion technology.

In March 2020, Allergan plc a global pharmaceutical company with more than 70 years of heritage in eye care announced that the U.S. Food and Drug Administration (FDA) has approved the company's New Drug Application (NDA) for DURYSTA™ (bimatoprost implant) 10 mcg for intracameral administration

In October 2017, Nicox S.A.  the international ophthalmic company, and pSivida Corp, a developer of sustained-release drug products and technologies announced their entry into a collaboration agreement to explore the potential of combining Nicox's nitric oxide (NO)-donating compounds with pSivida's bioerodible sustained release drug delivery system, to develop a sustained release drug to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension

Intraocular Pressure, also known as the IOP, is usually measured by a specialized medical device known as the Intraocular Pressure (IOP) monitor. This medical device is placed on the eye itself and measures eye pressure from multiple angles. In order for one to have high levels of IOP, one must regularly measure their IOP by the use of an Intraocular Pressure Monitor, which measures a patient's IOP and thus the pressure of lens or eyeballs. The lens, however, should never be placed inside of the patient's eye, unless the monitor is specifically designed to do just that. This disease causes severe vision loss and is usually caused by the buildup of internal pressure inside the eye. Once this pressure rises, it causes damage to the optic nerve and leads to loss of vision. New drugs from this company called Lumigan showed promising results in animal models of angle-closure glaucoma.